Invention Grant
- Patent Title: Esketamine for the treatment of depression
-
Application No.: US17711277Application Date: 2022-04-01
-
Publication No.: US11883526B2Publication Date: 2024-01-30
- Inventor: Jaskaran Singh , Ella Daly , Margaret Fedgchin , David Hough , Vanina Popova
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Agency: BakerHostetler
- Main IPC: A61K31/135
- IPC: A61K31/135 ; A61K9/00 ; A61P25/24

Abstract:
The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.
Public/Granted literature
- US20220362144A1 ESKETAMINE FOR THE TREATMENT OF DEPRESSION Public/Granted day:2022-11-17
Information query